Quantification of urinary allantoin by capillary zone electrophoresis during recombinant urate oxydase (rasburicase) therapy.
OBJECTIVE
Rasburicase (Fasturtec) is used to prevent or treat hyperuricemia associated with chemotherapy. We developed a capillary zone electrophoresis method to measure urinary allantoin, the degradation product of uric acid by rasburicase.


METHODS
Electrophoresis was performed using a P/ACE 5500 system (Beckman) with a fused silica capillary tube and a UV-visible detector set at 214 nm. Urine samples from 10 patients with non-Hodgkin's lymphoma were analyzed to validate the technique.


RESULTS
Using a sodium tetraborate running buffer, urinary allantoin was separated from related compounds and internal standard in less than 30 min. The method was linear up to 1.25 g/L (quantification limit: 30 mg/L); precision was below 10%. The total amount of allantoin excreted in patients treated by rasburicase ranged from 1.5 g to 7.9 g/4 days.


CONCLUSIONS
This CZE assay is a simple, rapid and reproducible method to measure allantoin in urine. Different elimination profiles have been found in patients treated with rasburicase.
Kattygnarath
D
D
Laboratoire de Biochimie A, AP-HP, 1 Avenue Claude Vellefaux, 75010 Paris, France.
Mounier
N
N
Madelaine-Chambrin
I
I
Gourmel
B
B
Le Bricon
T
T
Gisselbrecht
C
C
Faure
P
P
Houzé
P
P
D000481:Allantoin / Q000652:urine*; D015415:Biomarkers; D019075:Electrophoresis, Capillary; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000652:urine; D011994:Recombinant Proteins / Q000235:genetics / Q000627:therapeutic use*; D014503:Urate Oxidase / Q000235:genetics / Q000627:therapeutic use*
D015415:Biomarkers; D011994:Recombinant Proteins; C469709:rasburicase; D000481:Allantoin; D014503:Urate Oxidase